PharmacyCodes



Bleomycine [INN-French] en es it fr

Bleomycine [INN-French] Brand names, Bleomycine [INN-French] Analogs

Bleomycine [INN-French] Brand Names Mixture

  • No information avaliable

Bleomycine [INN-French] Chemical_Formula

C55H84N17O21S3

Bleomycine [INN-French] RX_link

http://www.rxlist.com/cgi/generic3/bleomycin.htm

Bleomycine [INN-French] fda sheet

http://www.accessdata.fda.gov/scripts/cder/onctools/labels.cfm?GN=bleomycin

Bleomycine [INN-French] msds (material safety sheet)

Bleomycine_[INN-French] MSDS

Bleomycine [INN-French] Synthesis Reference

T. Takita et al., ibid. 254

Bleomycine [INN-French] Molecular Weight

1415.56 g/mol

Bleomycine [INN-French] Melting Point

71 oC

Bleomycine [INN-French] H2O Solubility

Soluble

Bleomycine [INN-French] State

Solid

Bleomycine [INN-French] LogP

No information avaliable

Bleomycine [INN-French] Dosage Forms

Injection; Powder for solution

Bleomycine [INN-French] Indication

For palliative treatment in the management malignant neoplasm (trachea, bronchus, lung), squamous cell carcinoma, and lymphomas.

Bleomycine [INN-French] Pharmacology

Bleomycin is an antibiotic which has been shown to have antitumor activity. Bleomycin selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of mitomycin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed. Bleomycin has been shown in vitro to inhibit B cell, T cell, and macrophage proliferation and impair antigen presentation, as well as the secretion of interferon gamma, TNFa, and IL-2. The antibiotic antitumor drugs are cell cycle-nonspecific except for Bleomycin (which has major effects in G2 and M phases).

Bleomycine [INN-French] Absorption

Systemic absorption is approximately 45%.

Bleomycine [INN-French] side effects and Toxicity

Excessive exposure may cause fever, chills, nausea, vomiting, mental, confusion, and wheezing. Bleomycin may cause irritation to eyes, skin and respiratory tract. It may also cause a darkening or thickening of the skin. It may cause an allergic reaction.

Bleomycine [INN-French] Patient Information

Bleomycin should only be administered under the supervision of a qualified
healthcare provider experienced in the use of cancer chemotherapeutic agents.
Serious side effects have been reported with the use of bleomycin including: allergic
reactions (difficulty breathing; closing of the throat; swelling of the lips, tongue,
or face; or hives); a severe reaction consisting of low blood pressure, mental confusion,
fever, chills, and wheezing; pulmonary fibrosis (a lung condition); and others. Talk to
your doctor about the possible side effects from treatment with bleomycin.

Bleomycine [INN-French] Organisms Affected

Humans and other mammals